Figure 2. SFK inhibition prevents the dormant-to-proliferative switch of D2.0R cells in fibrotic lungs but does not lead to regression of established lesions.

(A) Total lung surface burden of CD1^nu/nu mice receiving Ad-empty (No fibrosis) or Ad–TGF-β^223/225 (Fibrosis) and tail-vein injections of 1 × 10⁶ D2.0R GFP cells, followed 24 hours later by 50 mg/kg body weight of AZD0530 daily for 21 days. (B) Lesions <1,000 pixels² represent single dormant cells and lesions >1,000 pixels² represent proliferative lesions. (C) Similar experiment as in A using 10⁶ shNT D2.0R GFP or shSrc D2.0R GFP cells (clones 3 and 4). Lungs were evaluated 21 days after tail-vein injections. (D) Lesion distribution as determined in B. (E and F) Intervention experiment: experiment as in A, except gavage with 50 mg/kg body weight of AZD0530 was started 21 days after tail-vein injection of cells (schematic provided in E). (F) Lesion distribution determined as in B. No significant difference was detected between groups.